Cite
HARVARD Citation
Blauvelt, A. et al. (n.d.). 322 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2). British journal of dermatology. p. . [Online].